المؤلفون: Neeraj Agarwal, G. A. Bjarnason, Jennifer J. Knox, Takeshi Yuasa, J. J. Ko, Lori Wood, Min-Han Tan, Lauren C. Harshman, Sandy Srinivas, Toni K. Choueiri, Brian I. Rini, Aristotle Bamias, Nils Kroeger, Mary J. MacKenzie, Sumanta K. Pal, Sun Young Rha, Daniel Y. Heng, Ulka N. Vaishampayan, J.-L. Lee, Frede Donskov

المصدر: British Journal of Cancer
Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A & Heng, D Y C 2014, ' First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC ', B J C, vol. 110, no. 8, pp. 1917-22 . https://doi.org/10.1038/bjc.2014.25

مصطلحات موضوعية: Male, Vascular Endothelial Growth Factor A, Oncology, Cancer Research, medicine.medical_specialty, mTOR inhibitor, overall survival, Population, Antineoplastic Agents, Context (language use), metastatic renal cell carcinoma, Disease-Free Survival, Renal cell carcinoma, Internal medicine, benchmarks, Carcinoma, medicine, Humans, international metastatic renal cell cancer database consortium, Molecular Targeted Therapy, Neoplasm Metastasis, education, Carcinoma, Renal Cell, Survival analysis, Aged, Proportional Hazards Models, Aged, 80 and over, Clinical Trials as Topic, education.field_of_study, Proportional hazards model, business.industry, TOR Serine-Threonine Kinases, Clinical study design, Middle Aged, medicine.disease, Survival Analysis, Surgery, outcomes assessment, Clinical trial, Treatment Outcome, targeted molecular therapy, Clinical Study, Female, business, progression-free survival, VEGF inhibitor

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7c53da20074d051bb32b5bf28fd77f3
https://doi.org/10.1038/bjc.2014.25

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.